HIV/AIDS is a worldwide pandemic afflicting 40 million people, and currently there is no cure. The proposed research is to develop a new reporter cell line to facilitate the discovery of novel anti-HIV drugs. This prospective reporter cell system will employ a Rev-dependent lentiviral vector, which has been shown previously to be highly specific to HIV infection. This novel system will greatly facilitate the development of a novel cell- based drug screening platform. Additionally, by employing two reporters this system can be used in multiple assay formats and would be amenable to high-throughput screens for antiretroviral compounds.
This NIH R03 Small Research Program grant is to develop a new research methodology, namely, the development of a new Rev-dependent cell line to screen for anti-HIV drugs. HIV infection causes AIDS that afflicted approximately 40 million people globally. This proposed research will facilitate the development of new therapeutics.
|Spear, Mark; Guo, Jia; Turner, Amy et al. (2014) HIV-1 triggers WAVE2 phosphorylation in primary CD4 T cells and macrophages, mediating Arp2/3-dependent nuclear migration. J Biol Chem 289:6949-59|
|Spear, Mark; Guo, Jia; Wu, Yuntao (2013) Novel anti-HIV therapeutics targeting chemokine receptors and actin regulatory pathways. Immunol Rev 256:300-12|
|Spear, Mark; Guo, Jia; Wu, Yuntao (2012) The trinity of the cortical actin in the initiation of HIV-1 infection. Retrovirology 9:45|
|Guo, Jia; Xu, Xuehua; Yuan, Wen et al. (2012) HIV gp120 is an aberrant chemoattractant for blood resting CD4 T cells. Curr HIV Res 10:636-42|